Vitamin D levels and busulphan kinetics in patients undergoing hematopoietic stem cell transplantation, a multicenter study-Reference-Cited by-同舟云学术

Vitamin D levels and busulphan kinetics in patients undergoing hematopoietic stem cell transplantation, a multicenter study

Published:2020-10-21 Issue:4 Volume:56 Page:807-817
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

El-Serafi Ahmed^ORCID,He Rui,Zheng Wenyi^ORCID,Benkossou Fadwa,Oerther Sandra,Zhao Ying,Mellgren Karin,Gustafsson Britt,Heilmann Carsten,Kanerva Jukka,Lotfi Kourosh,Toporski Jacek^ORCID,Sundin Mikael^ORCID,Höglund Martin,Mattsson Jonas,El-Serafi Ibrahim^ORCID,Hassan Moustapha^ORCID

Funder

Cancerfonden

Barncancerfonden

Radiumhemmets Forskningsfonder

Karolinska Institutet

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-020-01091-y.pdf

Reference72 articles.

1. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol. 1993;20:18–25. quiz 26.

2. Hassan M, Ehrsson H, Ljungman P. Aspects concerning busulfan pharmacokinetics and bioavailability. Leuk Lymphoma. 1996;22:395-&.

3. Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D, et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transpl. 2008;14:220–8.

4. Andersson BS, Thall PF, Madden T, Couriel D, Wang XM, Tran HT, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002;8:477–85.

5. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit. 1998;20:543–9.